Children with a rare, devastating brain disease may soon have their first treatment option in BioMarin’s Brineura.

With its MS meds under pressure, Biogen is looking to M&A to boost its future, hunting deals that would build on its success with drugs like Spinraza.

Klick Health's Klick Labs created a programmable device that simulates Parkinson's disease tremors in a bid to create empathy and study its effect on…

Allergan’s new "Toilet Talk" campaign seeks to normalize bowel health conversations—and the more candid, the better.

GlaxoSmithKline came up short in efforts to convince a jury that it shouldn’t be liable for a Chicago lawyer’s 2010 suicide while he was on generic Paxil.

Valeant unveiled the sticker on its new psoriasis drug Siliq—and at $3,500 per month it’s the lowest for next-gen meds.

The FDA is ordering major label changes on pain meds codeine and tramadol that will affect dozens of companies.

Novartis' CEO said China's pharma market will surpass $300 billion by 2020, Hanmi failed to report olmutinib side effect on time, Celgene tapped…

Bernstein’s Tim Anderson is warning of a “patent cliff 2.0.”